What is Inscripta?
Headquartered in Boulder, Colorado, Inscripta is the developer of the world's first benchtop platform for scalable digital genome engineering. The company’s integrated ecosystem—comprising specialized instrumentation, proprietary consumables, advanced software, and precise assays—facilitates a fully automated workflow. This infrastructure enables researchers to perform massively parallel, trackable editing of single cells at an unprecedented scale, effectively democratizing access to sophisticated genetic modification tools. By bridging the gap between digital design and biological execution, Inscripta is fundamentally altering how scientists approach functional genomics and synthetic biology.
How much funding has Inscripta raised?
Inscripta has raised a total of $417.5M across 6 funding rounds:
Series A
$6M
Series B
$23M
Series C
$55.5M
Series D
$125M
Unspecified
$58M
Series E
$150M
Series A (2016): $6M, investors not publicly disclosed
Series B (2017): $23M led by Paladin Capital Group, Spruce/MLS, Venrock Healthcare Partners, NanoDimension, and Foresite Capital
Series C (2018): $55.5M supported by Paladin Capital Group, Venrock, and Mérieux Développement
Series D (2019): $125M featuring MLS Capital, Oak HC/FT, JS Capital Management LLC, Venrock, Mérieux Développement, Paladin Capital Group, Foresite, and NanoDimension
Unspecified (2020): $58M, investors not publicly disclosed
Series E (2021): $150M with participation from Fidelity Management Corporation and T. Rowe Price
Key Investors in Inscripta
Paladin Capital Group
Paladin Capital Group is a global multi-stage investment firm that provides venture capital and growth financing, focusing on companies with strong leadership and clear pathways to market expansion.
Venrock
A historic venture capital firm founded in 1969, Venrock partners with founders to build high-growth technology and healthcare companies through deep industry expertise and strategic guidance.
T. Rowe Price
T. Rowe Price is a global asset management organization that utilizes active investment management and fundamental research to support long-term growth across diverse market sectors.
What's next for Inscripta?
With the support of major institutional backers, Inscripta is poised to transition into a phase of broader commercial expansion and platform optimization. The recent strategic capital will likely be directed toward enhancing the throughput of its CRISPR-based systems and expanding its footprint in both academic and industrial research environments. As the company continues to refine its automated workflows, the focus will shift toward establishing long-term partnerships and driving the adoption of its technology as a standard for high-throughput cellular research. The firm remains well-positioned to capitalize on the growing demand for precision engineering in the life sciences, leveraging its strong balance sheet to maintain its competitive edge in the rapidly evolving digital biology market.
See full Inscripta company page
